



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#6/A
10-13-01
RECEIVED
SEP 27 2001
TECHCENTER 1600/2900

In re Application of:

Lollar

: Group Art Unit: 1653

Serial No.: 09/435,403

: Examiner: H. Schnizer

Filed: November 5, 1999

For: GLYCOSYLATED, LOW
ANTIGENICITY, LOW
IMMUNOGENICITY FACTOR VIII

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C., 20231	
Date <u>9/10/01</u>	<u>Nina Reel</u> Nina Reel

RESPONSE TO OFFICE ACTION AND AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action dated March 12, 2001, Applicants respectfully request reconsideration of the rejection and entry of this Amendment.

In the Specification:

Please replace the second paragraph at page 1 with the following:

a, Hemophilia A is defined as hereditary deficiency of blood coagulation fVIII. fVIII is synthesized as a \approx 300 kDa single chain protein with internal sequence homology that defines the "domain" sequence NH₂-A1-A2-B-A3-C1-C2-COOH (Fig. 1). Domains are commonly delineated as A1 (Ala1-Arg372), A2 (Ser373-Arg740), B (Ser741-Arg1648), and A3-C1-C2 (Ser1690-Tyr2332). Despite its large size, the B domain of fVIII has no known function and can be deleted. fVIII is